Arcturus Therapeutics reported first-quarter 2026 GAAP earnings per share of -$0.95, exceeding analyst expectations by $0.04 [1].

The results highlight a divergence between the company's cost management and its top-line growth, as a significant revenue shortfall coincided with a modest earnings beat.

For the quarter ended March 2026, the company posted revenue of $2.06 million [1]. This figure missed analyst forecasts by $4.81 million [1]. This shortfall represents a revenue surprise of -73.79% [2].

Despite the revenue gap, the company's bottom line performed better than anticipated. The GAAP earnings per share of -$0.95 resulted in an earnings surprise of +16.91% [2].

Arcturus Therapeutics, which trades under the ticker ARCT, said these figures in its quarterly financial performance release [2]. The data indicates that while the company is managing its expenditures to beat EPS estimates, it is struggling to meet the revenue targets set by market analysts, a common trend for biotechnology firms in development phases.

“GAAP earnings per share of -$0.95, exceeding analyst expectations by $0.04”

The gap between the earnings beat and the steep revenue miss suggests that Arcturus Therapeutics may be reducing operating expenses or benefiting from one-time accounting adjustments rather than growing its commercial base. For a science-based company, a 73.79% revenue miss is a significant indicator that product monetization or partnership milestones are not progressing at the rate analysts expected.